Our recent genetic analysis revealed that MVNTs harbor frequent MAP2K1 exon 2 mutations or small in-frame deletions, as well as BRAF mutations other than V600E [28]; however, MAP kinase pathway activation in gangliogliomas appears to occur independently of MAP2K1 alterations. The gene discussed is BRAF; the disease is ganglioglioma.